UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________________________________________________________ FORM 10-K __________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38796 _____ ...

Corporate Presentation August 2022 Forward Looking Statement 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and ...

Corporate Presentation April 2022 Forward Looking Statement 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q3 2021 Earnings Conference Call November 8, 2021 4:15 PM ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard Aranda - Chief Medical Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co. Joseph Schwartz - SVB Leerink Carter Gould - Barclays Bank Olivia Brayer - Bank of America Merrill Lynch Operator Good day, and thank you for standing by. Welcome to the Gossamer Bio Q3 Earnings Call. [Operator ...

Q2:2021 Earnings Update August 2021 Forward Looking Statement 2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current an ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q2 2021 Earnings Conference Call August 9, 2021 4:30 PM ET Company Participants Bryan Giraudo - Chief Financial Officer Faheem Hasnain - Chairman, Co-Founder and Chief Executive Officer Richard Aranda - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB Leerink Olivia Brayer - Bank of America Merrill Lynch Patrick Trucchio - H.C. Wainwright Emma Nealon - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the Gossamer Bio Q2 Ea ...

go frame bio 1 Corporate Presentation February 2021 Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results ...

Gossamer Bio, Inc. (NASDAQ:GOSS) Q4 2020 Earnings Conference Call February 25, 2021 8:30 AM ET Company Participants Bryan Giraudo - CFO Faheem Hasnain - Co-Founder, CEO, & Chairman Richard Aranda - SVP, Clinical Development Conference Call Participants Unidentified Analyst - Carter Gould - Barclays Bank Emma Nealon - Cantor Fitzgerald & Co. Olivia Brayer - Bank of America Securities Patrick Trucchio - H.C. Wainwright & Co Unidentified Analyst - SMBC Operator Ladies and gentlemen, thank you for standing ...

go frame bio 1 Corporate Presentation November 2020 Forward Looking Statement This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results ...

Start Time: 16:30 January 1, 0000 5:30 PM ET Gossamer Bio, Inc. (NASDAQ:GOSS) Q3 2020 Earnings Conference Call November 10, 2020, 16:30 PM ET Company Participants Sheila Gujrathi - Co-Founder and CEO Bryan Giraudo - CFO Luisa Salter-Cid - Chief Scientific Officer Richard Aranda - SVP, Head of Clinical Development Conference Call Participants Tyler Van Buren - Piper Sandler Joseph Schwartz - SVB Leerink Geoff Meacham - Bank of America Merrill Lynch Josh Schimmer - Evercore ISI Carter Gould - Barclays Emma Ne ...